DelveInsight’s Biologics Market Insights Report 2034 provides the current and forecast market analysis, individual leading Biologics Companies market shares, challenges, Biologics Market Drivers, barriers, trends, and key Biologics Companies shaping the global market landscape. The report delivers comprehensive insights into market dynamics, competitive developments, product innovations, regulatory analysis, and emerging opportunities across major regions, helping stakeholders make informed strategic business decisions in the rapidly evolving biologics industry.
To read more about the latest highlights related to the Biologics Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/biologics-market
Key Takeaways from the Biologics Market Report
- In October 2025, Sartorius AG launched its Flexsafe Pro bioprocessing bag platform designed specifically for advanced mammalian cell fermentation processes, helping manufacturers improve biologics safety and scalability in large-scale production environments.
- The Biologics Market is estimated to grow at a CAGR of 9.54% during the forecast period from 2026 to 2034.
- North America is expected to account for the highest proportion of the Biologics Market in 2025, out of all regions. North America is also expected to dominate the overall Biologics Market during the given forecast period from 2026 to 2034.
- The leading Biologics Companies such as GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc., Novo Nordisk, Novartis AG, Pfizer Inc., AstraZeneca, Bristol Myers Squibb, Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc., Biogen, bluebird bio, Inc., Janssen Global Services, LLC., Cellitron Group, and others.
To know more about why North America is leading the market growth in the Biologics Market, get a snapshot @ https://www.delveinsight.com/sample-request/biologics-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Biologics Market Dynamics
The rising prevalence of chronic and complex diseases, rapid expansion of monoclonal antibodies, growing adoption of cell and gene therapies, and increasing investments in biopharmaceutical research and development are collectively accelerating the Biologics Market. As the global burden of diseases such as cancer, autoimmune disorders, rheumatoid arthritis, influenza, and rare genetic conditions continues to rise, the demand for highly targeted, personalized, and effective biologic therapies is increasing significantly. Biologics have become an essential treatment option because of their ability to provide improved therapeutic outcomes for conditions that often have limited treatment alternatives.
According to the International Agency for Research on Cancer (2026), global cancer cases are projected to reach 32.6 million by 2045, highlighting the growing need for advanced biologic therapies in oncology. Additionally, the World Health Organization (2023) reported that approximately 18 million people were living with rheumatoid arthritis worldwide, while around 1 billion cases of seasonal influenza occur globally every year. The increasing prevalence of these chronic and infectious diseases is driving greater adoption of monoclonal antibodies, recombinant proteins, vaccines, and other biologic therapies across multiple therapeutic areas.
Furthermore, continuous innovation in biologic drug development, expanding clinical pipelines, and strong investments in manufacturing infrastructure are expected to support the long-term growth of the Biologics Market during the forecast period from 2026 to 2034.
Biologics Market Segmentation Analysis
Biologics Market by Product Type (Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Proteins, and Others), Source (Mammalian, Microbial, and Viral Vector), Application (Oncology, Immunology, Infectious Diseases, Neurological Diseases, and Others), Manufacturing Type (In-House and Outsourced), End-Users (Biopharmaceutical Companies, Contract Research Organizations (CROs), and Contract Development & Manufacturing Organizations (CDMOs)), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Product Type segment of the Biologics Market, the Monoclonal Antibodies category is projected to hold the largest market share in 2025. This can be attributed to its high therapeutic specificity, strong clinical efficacy, expanding applications across oncology, autoimmune diseases, infectious diseases, and neurological disorders, along with continuous advancements in antibody engineering, bispecific antibodies, and next-generation immunotherapies.
Get a sneak peek at the @ Biologics Market Dynamics
Biologics Market Insights
According to the American Cancer Society (2026), approximately 2,114,850 new cancer cases are projected to occur in the United States in 2026. The increasing prevalence of cancer, autoimmune disorders, metabolic conditions, neurological diseases, and rare genetic disorders is significantly driving demand for biologics, including monoclonal antibodies, recombinant proteins, CAR-T therapies, gene therapies, and advanced vaccines. Increasing investments in manufacturing infrastructure and clinical development are further strengthening the global Biologics Market.
Biologics Companies
GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc., Novo Nordisk, Novartis AG, Pfizer Inc., AstraZeneca, Bristol Myers Squibb, Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc., Biogen, bluebird bio, Inc., Janssen Global Services, LLC., Cellitron Group, and others.
Biologics Market Drivers
The Biologics Market is poised for substantial growth owing to the rising prevalence of chronic and complex diseases, rapid expansion of monoclonal antibodies, increasing adoption of cell and gene therapies, growing investments in biopharmaceutical R&D, advancements in biologics manufacturing technologies, expanding biosimilar adoption, and supportive regulatory approvals during the forecast period from 2026 to 2034.
Which MedTech and Biopharma key players in the Biologics Market are set to emerge as the trendsetter? Explore @ https://www.delveinsight.com/sample-request/biologics-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=mpr
Scope of the Biologics Market Report
- Coverage – Global
- Study Period – 2023–2034
- Base Year – 2025
- Forecast Period – 2026–2034
- Biologics Companies – GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc., Novo Nordisk, Novartis AG, Pfizer Inc., AstraZeneca, Bristol Myers Squibb, Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc., Biogen, bluebird bio, Inc., Janssen Global Services, LLC., Cellitron Group, and others.
Interested in knowing the Biologics Market by 2034? Click to get a snapshot of the @ Biologics Market Trends
Table of Contents
- Biologics Market Report Introduction
- Biologics Market Executive Summary
- Competitive Landscape
- Regulatory Analysis
- Biologics Market Key Factors Analysis
- Biologics Market Porter’s Five Forces Analysis
- Biologics Market Assessment
- Biologics Market Company and Product Profiles
- KOL Views
- Project Approach
- About DelveInsight
- Disclaimer & Contact Us
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
